Trial Profile

Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment in Triple-negative Breast Cancer.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 27 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Paclitaxel (Primary) ; Cisplatin; Cyclophosphamide; Epirubicin
Indications Early breast cancer; Triple negative breast cancer
Focus Therapeutic Use

Most Recent Events

13 Apr 2022 Results presented at the 113th Annual Meeting of the American Association for Cancer Research
08 Jun 2021 Results of a 8 years of median follow-up analysis presented at the 57th Annual Meeting of the American Society of Clinical Oncology
11 Feb 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com